278 related articles for article (PubMed ID: 33273263)
21. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
[TBL] [Abstract][Full Text] [Related]
22. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
23. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
[TBL] [Abstract][Full Text] [Related]
25. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
26. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ
Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076
[No Abstract] [Full Text] [Related]
27. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
28. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M
Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
31. Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
Krečak I; Čengić M; Skorić I; Nakić M; Gverić-Krečak V
Ann Hematol; 2021 Nov; 100(11):2861-2862. PubMed ID: 34109444
[No Abstract] [Full Text] [Related]
32. Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.
Patel JN; Singh J; Ghosh N
Oncotarget; 2024 Jun; 15():355-359. PubMed ID: 38829647
[TBL] [Abstract][Full Text] [Related]
33. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
34. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
35. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib's off-target mechanism: cause for dose optimization.
Zimmerman SM; Peer CJ; Figg WD
Cancer Biol Ther; 2021 Dec; 22(10-12):529-531. PubMed ID: 34632931
[TBL] [Abstract][Full Text] [Related]
37. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
39. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
[TBL] [Abstract][Full Text] [Related]
40. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Lasica M; Tam CS
Hematol Oncol Clin North Am; 2021 Aug; 35(4):761-773. PubMed ID: 34174985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
